Insulin
Insulin. 51-residue disulfide-bridged peptide hormone. Binds insulin receptor (RTK) → GLUT4 translocation → glucose uptake + glycogen + fat + protein synthesis. Many…
51-residue disulfide-bridged peptide hormone. Binds insulin receptor (RTK) → GLUT4 translocation → glucose uptake + glycogen + fat + protein synthesis. Many analogs: rapid-acting (lispro, aspart, glulisine), short (regular), intermediate (NPH), long (glargine, detemir, degludec). Analogs vary by fatty-acid acylation, pI shift, or amino-acid substitution.
PK REMOVED. ITS INTRAVENOUS VOLUME IS REFUTED BY ITS OWN PAPER AND ITS SUBCUTANEOUS HALF-LIFE IS A PEAK TIME. That citation states "a fractional insulin loss rate of 0.112 +/- 0.063 min(1) and A DISTRIBUTION VOLUME OF 15.6 +/- 4.0 L"; the record took the rate constant and substituted a volume a third of that, understating insulin clearance 3.09x against its own source and against the physiological figure. The subcutaneous row is worse: its citation reports no bioavailability, no volume and no half-life, and the ONLY "one hour" in that abstract is "peak serum IRI at 60 to 90 minutes after conventional SC insulin injection" — A PEAK TIME STORED AS A HALF-LIFE. That row is also absorption-limited by a factor of ten against the intravenous one and CARRIES NO ABSORPTION RATE AT ALL, so the single parameter that governs subcutaneous insulin was a solver fallback. BEYOND THAT THE SCHEMA CANNOT HOLD THIS RECORD: the dose block is empty for all four routes, insulin is dosed in international units with no conversion field, and "insulin" is not one molecule — this record own aliases name two long-acting analogues whose half-lives are twelve and over twenty-five hours against a stored subcutaneous one hour, and its own bibliography carries the review documenting the molecules its parameters do not describe. Its subcutaneous citation also had to SUPPRESS ENDOGENOUS SECRETION to measure exogenous drug at all, and the model has no endogenous baseline.
Sources: PMID:18715209, PMID:15738706, PMID:6341763